MAPKAPK2 and neuroblastoma: However, in a search of potential biomarkers in existing database, we evaluated the relationship of MAPKAPK2, MYC, or MYCN expression and patient survival in the NCI TARGET database of mRNA expression for 175 MYCN non-amplified primary neuroblastoma tumors28.